MAZE Stock Forecast & Price Target

Maze Therapeutics is supported by a compelling genetics-led pipeline in APOL1-mediated kidney disease and PKU, with MZE829 showing preliminary -49% uACR reductions in AMKD without type 2 diabetes and a clean safety profile that may differentiate it from inaxaplin’s liver enzyme elevations. The latest AMPLITUDE and PARASOL readouts strengthen the view that proteinuria reduction can translate into an accelerated-approval path, while Maze’s planned HORIZON update in 4Q26 could further validate efficacy across AMKD subgroups and inform dose optimization. Beyond MZE829, MZE782 adds durability to the investment case, with Phase 1 PK data showing 39-fold urinary Phe excretion at 960mg single dose and 42-fold at 240mg BID, plus a 2027 data readout that may support broader CKD and PKU opportunities.

Maze Therapeutics is a clinical-stage company with no approved products, so the thesis depends on two early programs, MZE829 and MZE782, clearing clinical, regulatory, and commercial hurdles that remain highly uncertain. Even after the April registered offering lifted cash to $495M and extended the expected runway into 2029, the business is still likely to need additional external funding, while any failure in development, approval, or market adoption could materially impair value. Competitive pressure from Vertex and others, plus the risk that Maze’s endpoints, labels, or efficacy profile do not clearly outperform existing options like SGLT2 inhibitors, makes the downside profile compelling.